UBS Group Issues Positive Forecast for Hologic (NASDAQ:HOLX) Stock Price

by · The Cerbat Gem

Hologic (NASDAQ:HOLX – Free Report) had its price objective hoisted by UBS Group from $84.00 to $90.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a neutral rating on the medical equipment provider’s stock.

Other research analysts have also recently issued research reports about the company. Evercore ISI boosted their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Royal Bank of Canada raised their price target on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday. Leerink Partners reduced their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and cut their target price for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Stephens reaffirmed an “overweight” rating and set a $92.00 price target on shares of Hologic in a research report on Tuesday, July 30th. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic has a consensus rating of “Moderate Buy” and an average target price of $89.25.

Check Out Our Latest Report on Hologic

Hologic Trading Down 5.9 %

Shares of HOLX opened at $78.80 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.32. Hologic has a 12 month low of $66.93 and a 12 month high of $84.67. The stock has a market cap of $18.30 billion, a PE ratio of 26.80, a P/E/G ratio of 2.98 and a beta of 0.98. The stock’s 50-day moving average is $81.06 and its two-hundred day moving average is $78.08.

Hologic (NASDAQ:HOLX – Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 17.59% and a return on equity of 19.53%. Hologic’s revenue for the quarter was up 4.5% on a year-over-year basis. During the same quarter last year, the company earned $0.89 earnings per share. Equities analysts forecast that Hologic will post 4.09 earnings per share for the current fiscal year.

Institutional Trading of Hologic

Several institutional investors have recently made changes to their positions in HOLX. Main Street Financial Solutions LLC increased its stake in shares of Hologic by 14.0% in the third quarter. Main Street Financial Solutions LLC now owns 3,683 shares of the medical equipment provider’s stock worth $300,000 after acquiring an additional 453 shares during the last quarter. GSA Capital Partners LLP lifted its stake in Hologic by 22.2% in the third quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock valued at $469,000 after acquiring an additional 1,048 shares during the last quarter. Entropy Technologies LP bought a new stake in Hologic in the third quarter worth approximately $1,025,000. Versor Investments LP bought a new position in shares of Hologic during the 3rd quarter valued at $1,677,000. Finally, Crossmark Global Holdings Inc. boosted its holdings in Hologic by 2.2% in the third quarter. Crossmark Global Holdings Inc. now owns 18,101 shares of the medical equipment provider’s stock worth $1,474,000 after purchasing an additional 393 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

(Get Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Featured Stories